Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells – An Analysis for Patients With Incurable Pancreatic Cancer

Abstract

Background/Aim: Adoptive immunotherapy (AIT) using autologous zoledronate-activated killer (ZAK) cells has been performed for developing a novel modality of cancer treatment. In this study, data series from incurable pancreatic cancer were analyzed. Patients and Methods: Patients were treated with AIT using intravenous administration of ZAK cells every 3 to 4 weeks in combination with standard chemotherapy and possible clinical benefits were examined. Results: Seventy-five patients were treated. A median overall survival (OS) time of 6.7 months was achieved for all patients and 13.1 months for those treated 5 times or more, that increased to 14.6 and 18.3 months, respectively, when the previous treatment period of chemotherapy alone was included in the analysis. The disease control rate was 58.5 %. Multivariate regression analysis showed a significant positive correlation between the survival and baseline value of lymphocyte percentage in white blood cell counts (p=0.031). Conclusion: The data suggest that AIT using

Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports

“…3 To date, more than 600 patients with various cancer types have been treated with ZAK‐cell AIT. 4 , 5 Here, we summarize the cases of seven long‐term (>5‐year) survivors among the trial's patients with unresectable or metastatic cancer treated with ZAK‐cell AIT. We also discuss a possible role of ZAK‐cell AIT for cancer treatment.…”

“…Since 2009, we have introduced the use of zoledronate‐activated killer (ZAK) cells into the AIT trial 3 . To date, more than 600 patients with various cancer types have been treated with ZAK‐cell AIT 4,5 . Here, we summarize the cases of seven long‐term (>5‐year) survivors among the trial's patients with unresectable or metastatic cancer treated with ZAK‐cell AIT.…”